Abstract
The p53 protein is closely involved in the carcinogenesis of many kinds of cancers. Though the prognostic role of p53 expression for the survival of colorectal cancer (CRC) patients has been preliminarily identified, the prognostic effect of p53 expression in patients with completely resected CRC is still unclear. Therefore, a retrospective cohort study was performed to assess the prognostic role of p53 expression for overall survival in patients with completely resected CRC. A total of 153 patients (mean age 50.9 years) with completely resected CRC was finally included in the retrospective cohort study. Kaplan-Meier product-limit methods and log-rank test were used to estimate overall survival distribution and test the difference. In addition, multivariable analysis by Cox regression model was also used to test the prognostic role of p53 expression on overall survival by adjusting for other confounding factors. Of those 153 CRC patients, 62 (40.5 %) were positive for p53 protein expression in the tumor tissues. The log-rank test showed that there was an obvious difference in the overall survival between the p53-positive group and the p53-negative group (P < 0.001). Multivariable analysis by Cox regression model further showed that p53 protein expression was an independent predictor of shorter overall survival in patients with completely resected CRC (hazard ratio [HR] = 1.77; 95 % confidence interval [95 % CI] 1.15–2.71, P = 0.009). Therefore, p53 protein expression in the tumor tissue is an independent predictor of shorter overall survival in patients with completely resected CRC.
Similar content being viewed by others
References
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–47.
Peng H, Xie SK, Huang MJ, Ren DL. Associations of CYP2E1 rs2031920 nd rs383867 polymorphisms with colorectal cancer risk: a systemic review and meta-analysis. Tumor Biol. 2013;34(4):2389–95.
Pfister DG, Benson 3rd AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350(23):2375–82.
Custodio A, Barriuso J, de Castro J, Martinez-Marin V, Moreno V, Rodriguez-Salas N, et al. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013;39(8):908–24.
Guo Q, Dai SB, Shen F, Yu D, Shen ST, Zhang Q, et al. VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis. Tumor Biol. 2014;35(5):4977–82.
Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010;468(7323):572–5.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microrna processing by p53. Nature. 2009;460(7254):529–33.
Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, et al. Increases in p53 expression induce ctgf synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest. 2011;121(8):3343–56.
Ye Z, Cao Q, Niu G, Liang Y, Liu Y, Jiang L, et al. P63 and p53 expression in extranodal nk/t cell lymphoma, nasal type. J Clin Pathol. 2013;66(8):676–80.
Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT. Promoter methylation of igfbp-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer. 2009;8(1):120.
Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage iii colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.
Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-mulptile genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34(3):1901–11.
Ueda Y, Yasuda K, Inomata M, Shiraishi N, Yokoyama S, Kitano S. Biological predictors of survival in stage ii colorectal cancer. Mol Clin Oncol. 2013;1(4):643–8.
Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than her2 status is significantly associated with increased ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230–7.
Su WJ, Fang JS, Cheng F, Liu C, Zhou F, Zhang J. Rnf2/ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development. Proc Natl Acad Sci U S A. 2013;110(5):1720–5.
Cho SJ, Rossi A, Jung YS, Yan W, Liu G, Zhang J, et al. Ninjurin1, a target of p53, regulates p53 expression and p53-dependent cell survival, senescence, and radiation-induced mortality. Proc Natl Acad Sci U S A. 2013;110(5):9362–7.
Jiang L, Tao C, He A. Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis. Tumor Biol. 2013;34(2):1037–43.
De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. Kras, braf, pik3ca, and pten mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.
Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, et al. Prognostic significance of mucin and p53 expression in stage ib non-small cell lung cancer: a laboratory companion study to calgb 9633. J Thorac Oncol. 2010;5(6):810–7.
He S, Liu F, Xie Z, Zu X, Xu W, Jiang Y. P-glycoprotein/mdr1 regulates pokemon gene transcription through p53 expression in human breast cancer cells. Int J Mol Sci. 2010;11(9):3309–051.
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, et al. P53 expression in node-positive breast cancer patients: results from the cancer and leukemia group b 9344 trial (159905). Clin Cancer Res. 2011;17(15):5170–8.
Khaled HM, Bahnassy AA, Raafat AA, Zekri AR, Madboul MS, Mokhtar NM. Clinical significance of altered nm23-h1, egfr, rb and p53 expression in bilharzial bladder cancer. BMC Cancer. 2009;9(1):32.
Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, et al. Cancer/testis antigen cage exerts negative regulation on p53 expression through hdac2 and confers resistance to anti-cancer drugs. J Biol Chem. 2010;285(34):25957–68.
Zhang HT, Wang YL, Zhang J, Zhang QX. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumor Biol. 2014;35(2):1403–9.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, BW., Liu, Y., Liu, JR. et al. Prognostic effect of p53 expression in patients with completely resected colorectal cancer. Tumor Biol. 35, 9893–9896 (2014). https://doi.org/10.1007/s13277-014-2219-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-2219-z